A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
12/2004
12/07/2004	US6828299 Polyhydroxy glycopeptide derivatives
12/07/2004	US6828298 Glycoprotein having inhibitory activity against helicobacter pylori colonization
12/07/2004	US6828105 Methods of their use in inhibition of growth of viruses of the picornavirus, calicivirus, togavirus and flavivirus families, as in treatment of a viral infection. The antisense antiviral compounds are substantially uncharged oligomers having a
12/07/2004	US6827945 First ingredient obtainable from turmeric; a second ingredient obtainable from ginger; and a third ingredient obtainable from horseradish; treating viral infections
12/07/2004	US6827939 Amino acid sequences for use in detection and treatment of viral infection
12/07/2004	US6827935 Method of and compositions for immunization with the pseudomonas V antigen
12/07/2004	US6827926 Administering a porphyrin compound that coordinates gallium in the central pyrrolic core, and irradiating porphyrin compound with energy at a wavelength capable of exciting the molecule to achieve the desired detection or therapeutic effect
12/07/2004	CA2352332C Hygromycin a derivatives
12/07/2004	CA2287736C Furopyridine antibacterials
12/07/2004	CA2158834C Antisense oligos which interfere with mrna cap activity and inhibit translation
12/07/2004	CA2147755C 6-(substituted methylene) penems and intermediates
12/07/2004	CA2108817C Arylidene-1-azacycloalkanes and arylalkyl-1-azacycloalkanes, their salts, medicaments containing these compounds and their use, and processes for their preparation
12/02/2004	WO2004104010A1 Crystalline form of cefdinir
12/02/2004	WO2004103996A1 Hepatitis c inhibitor compounds
12/02/2004	WO2004103986A2 3-desoxyanthocyanidine compounds and uses thereof as antimicrobial agents
12/02/2004	WO2004103408A2 Vaccine composition comprising iron phosphate as a pharmaceutical aid to said vaccine
12/02/2004	WO2004103401A2 Avian combination-vaccine against e.coli and salmonella
12/02/2004	WO2004103399A1 Use of ulinastatin for treating severe acute respiratory syndrome and pharmaceutical composition of ulinastatin
12/02/2004	WO2004103396A1 Compositions for enhanced mucosal delivery of interferon alpha
12/02/2004	WO2004103373A1 Ophthalmic solution containing quinolone antimicrobial compound
12/02/2004	WO2004103366A1 Heterocyclic compounds useful to treat hcv
12/02/2004	WO2004103360A1 Compounds and preparaitons having antiviral effect
12/02/2004	WO2004103354A1 1´-acetoxychavicol acetate, enantiomers and derivatives thereof having anti-hiv activity
12/02/2004	WO2004103336A2 Drug delivery system
12/02/2004	WO2004103271A2 Disease prevention and vaccination prior to thymic reactivations
12/02/2004	WO2004103264A2 Hemostatic antibacterial composition and products incorporating the same
12/02/2004	WO2004087189A3 Use of bacteriocin for the amelioration of digestive functionality
12/02/2004	WO2004084935A3 Francisella strain for live vaccine
12/02/2004	WO2004083172A3 Process for the preparation of 7-amino (p-hydroxyphenylglyclyamido) cephem compounds
12/02/2004	WO2004076053A3 Chemical process for the preparation of intermediates to obtain n-formyl hydroxylamine compounds
12/02/2004	WO2004067563A8 Peptide inhibitors of toxins derived from ll-37
12/02/2004	WO2004026815A3 Phenol derivatives and their use as rotamase inhibitors
12/02/2004	WO2003063767A3 Rsv proteins, antibodies, compositions, methods and uses
12/02/2004	WO2003028632A3 Development of a preventive vaccine for filovirus infection in primates
12/02/2004	WO2003025119A3 Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies
12/02/2004	US20040242928 Reverse hydroxamic acid derivatives
12/02/2004	US20040242904 Novel sordarin derivative isolated from culture fermentations and functions as an antifungal agent
12/02/2004	US20040242884 3-Substituted-7-oxo-4,7-dihydro-thieno(3,2-b)pyridine-6-carboxylic acid benzylamide derivatives; for herpes viruses
12/02/2004	US20040242871 Nitric oxide synthease inhibitors; antiinflamamtory agents; analgesics; inflamamtory bowel disorders; antiarthritic agents;
12/02/2004	US20040242870 Antiviral methods and compounds
12/02/2004	US20040242868 Controlling cytokines; antiinflammatory agents; rheumatic disoreders; skin disorders; respiratory system disorders; Alzheimer's disease; Parkinson's disease; Huntington"s disease ; amyotrophic lateral sclerosis
12/02/2004	US20040242859 Moraxella (branhamella) catarrhalis polypeptides and corresponding dna fragments
12/02/2004	US20040242844 Nucleotide sequences coding streptococcus capsular polysaccharide antigens for use in diagnosis and prevention of infections in mammals; veterinary medicine
12/02/2004	US20040242700 Administering a warm blood animal an ambroxol, bromhexin or salts or mixtures for treating influenza virus
12/02/2004	US20040242672 Pyrrolidine derivatives
12/02/2004	US20040242659 Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof
12/02/2004	US20040242636 Enzyme inhibitors as antiinflammatory ageents for psoriasis, obesity
12/02/2004	US20040242614 Pharmaceutically active compounds and methods of use thereof
12/02/2004	US20040242612 Use of tyrosine kinase inhibitors for promoting hair growth
12/02/2004	US20040242591 phenyloxazolidinones derivatives that exhibit significantly greater antibacterial activity, than available with the present compounds against multiply resistant gram positive pathogens
12/02/2004	US20040242564 1,2,3,4-tetrahydroisoquinolines derivatives
12/02/2004	US20040242533 such as 5-iodo-O6-5'-cyclo-5,6-dihydro-3'-azido-3'-deoxythymidine for prophylaxis or diagnosis of viral diseases caused by hepatitis virus, herpes viruses such as Epstein-Barr virus
12/02/2004	US20040242488 Peptides having same amino acid sequence and same anti-microbial activity as those of Phylloseptins which are isolated from the skin of Phyllomedusa hypochondrialis; the 19-residue anti-microbial peptides are cationic and based on their primary structure, all peptides can fitted to an amphiphilic a-helix
12/02/2004	US20040242481 Use of hmgb1 for the activation of dendritic cells
12/02/2004	US20040242459 Method for treating inflammatory diseases by administering a ppar-delta agonist
12/02/2004	US20040242455 which exerts potent and selective activated blood coagulation factor X inhibitory activity and is useful for prevention or treatment of disease associated therewith
12/02/2004	US20040241826 Mycobacterial antigens expressed during latency
12/02/2004	US20040241803 25 human secreted proteins
12/02/2004	US20040241745 Substance specific to pd-1
12/02/2004	US20040241671 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their us as medicines
12/02/2004	US20040241641 Monoclonal antibody for prevention and treatment of human immunodeficiency viral infection; immunotherapy
12/02/2004	US20040241640 Internalisation of virus into cells
12/02/2004	US20040241248 Crosslinking the carboxylic acid groups in a glycosaiminoglycan with a primary amine in a lipid to form particles that can be used to encapsulate various drugs, especially chemotherapeutic agents
12/02/2004	US20040241235 Core of drug and binder having at least three successive coating layers starting from the core: a delayed or sustained release polymeric coating; a hydrophobic coating containing a waxy compound; and another polymeric coating having a complementary release function and conditioning the suspension medium
12/02/2004	US20040241226 Administering a tyrosine kinase inhibitor, more particularly a non toxic, potent and selective c-kit inhibitor, wherein said inhibitor is unable to promote death of IL-3 dependent cells cultured to presence of IL-3
12/02/2004	US20040241206 Use of nanoparticles as carriers for biocides in ophthalmic compositions
12/02/2004	US20040241187 An inactivated, disrupted influenza virus preparation of a hemagglutinin antigen stabilised by alpha-tocopherol succinate in the absence of thiomersal or at low levels of thiomersal; hemagglutinin detectable by a single radial immunoassay (SRID); mercury-free preservative; administering by any route
12/02/2004	US20040241182 lymphocytes; immunogens; fusion proteins; for treatment/prevention of infection
12/02/2004	US20040241181 Preferentially inducing a more potent CD8+ T cell response to an immunogen by delivering a recombinant simian adenovirus comprising a nucleic acid molecule encoding an immunogen under the control of gene expression regulatory sequences directing expression of the immunogen; HIV; rabies; papilloma virus
12/02/2004	US20040241147 antigen presenting cells which express major histocomatibility complexes, used as vaccines
12/02/2004	US20040241140 Expression vectors able to elicit improved immune response and methods of using same
12/02/2004	DE10061195B4 Verwendung von Abformmassen zur Herstellung von Behandlungsvorrichtungen Use of impression materials for the production of treatment devices
12/02/2004	CA2528521A1 Disease prevention and vaccination prior to thymic reactivations
12/02/2004	CA2489124A1 Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
12/01/2004	EP1482037A1 Inhibition of gene expression by delivery of specially selected double stranded or other forms of small interfering RNA precursors enabling the formation of small interfering RNA in vivo and in vitro
12/01/2004	EP1481989A1 A-33 related antigens and their pharmacological uses
12/01/2004	EP1481986A1 Antibiotic 97518, pharmaceutically acceptable salts and compositions, and use thereof
12/01/2004	EP1481985A1 Modified hepatitis C virus (HCV) NS3 for medical treatment
12/01/2004	EP1481984A1 Modified hepatitis C virus (HCV) NS5
12/01/2004	EP1481983A1 Nucleoside analogues and oligonucleotide derivative comprising nucleotide analogue thereof
12/01/2004	EP1481969A1 Piperidine derivative compounds and drugs containing the compounds as the active ingredient
12/01/2004	EP1481966A1 Novel arylamidine derivative or salt thereof
12/01/2004	EP1481250A2 Methods of screening apoptosis modulating compounds, compounds identified by said methods and use of said compounds as therapeutic agents
12/01/2004	EP1481011A1 Monoclonal and polyclonal antibodies recognizing coagulase-negative staphylococcal proteins
12/01/2004	EP1481006A2 Universal antimicrobial treatment
12/01/2004	EP1481005A1 Dab sp 9 /sp DERIVATIVES OF LIPOPEPTIDE ANTIBIOTICS AND METHODS OF MAKING AND USING THE SAME
12/01/2004	EP1481001A2 Prion inhibiting peptides and derivatives thereof
12/01/2004	EP1481000A2 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
12/01/2004	EP1480997A2 Haemophilus adherence and penetration proteins
12/01/2004	EP1480993A2 Desaturase genes, enzymes encoded thereby, and uses thereof
12/01/2004	EP1480982A2 Modified fluorinated nucleoside analogues
12/01/2004	EP1480975A2 Chemical compounds
12/01/2004	EP1480973A1 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
12/01/2004	EP1480971A1 Isoquinoline derivatives
12/01/2004	EP1480962A1 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
12/01/2004	EP1480958A1 Uracil-thioether
12/01/2004	EP1480941A2 Urea derivatives as hiv aspartyl protease inhibitors
12/01/2004	EP1480671A2 Recombinant rsv virus expression systems and vaccines
12/01/2004	EP1480656A1 Hyaluronic acid mediated adenoviral transduction
12/01/2004	EP1480653A2 Ribavirin syrup formulations

1 ... 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 ... 1798